Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33:115–54.

Article  CAS  PubMed  Google Scholar 

Iwasaki K, Barroga E, Enomoto M, Tsurui K, Shimoda Y, Matsumoto M, et al. Long-term surgical outcomes of gastric neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasms. World J Surg Oncol. 2022;20:165.

Article  PubMed  PubMed Central  Google Scholar 

Kang SH, Kim KH, Seo SH, An MS, Ha TK, Park HK, et al. Neuroendocrine carcinoma of the stomach: a case report. World J Gastrointest Surg. 2014;6:77–9.

Article  PubMed  PubMed Central  Google Scholar 

Hu P, Bai J, Liu M, Xue J, Chen T, Li R, et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastr Cancer. 2020;23:591–9.

Article  CAS  Google Scholar 

Ma F, Wang B, Xue L, Kang W, Li Y, Li W, et al. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach. J Cancer Res Clin Oncol. 2020;146:2135–42.

Article  CAS  PubMed  Google Scholar 

Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(346–60): e7.

Google Scholar 

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, et al. An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping. Cell. 2020;183(1420–35): e21.

Google Scholar 

Tendler S, Kanter L, Lewensohn R, Ortiz-Villalon C, Viktorsson K, De Petris L. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy. PLoS ONE. 2020;15: e0240973.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Metovic J, La Salvia A, Rapa I, Napoli F, Birocco N, Pia Bizzi M, et al. Molecular subtypes of extra-pulmonary neuroendocrine carcinomas identified by the expression of neuroendocrine lineage-specific transcription factors. Endocr Pathol. 2022;33:388–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, et al. DLL3 as an emerging target for the treatment of neuroendocrine neoplasms. Oncologist. 2022;27:940–51.

Article  PubMed  PubMed Central  Google Scholar 

Rudin CM, Reck M, Johnson ML, Blackhall F, Hann CL, Yang JC, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16:66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15:1823–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yachida S, Totoki Y, Noe M, Nakatani Y, Horie M, Kawasaki K, et al. Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system. Cancer Discov. 2022;12:692–711.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautes-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev. 2016;271:260–75.

Article  CAS  PubMed  Google Scholar 

Ding GY, Ma JQ, Yun JP, Chen X, Ling Y, Zhang S, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol. 2022;76:608–18.

Article  CAS  PubMed  Google Scholar 

Horeweg N, Workel HH, Loiero D, Church DN, Vermij L, Leon-Castillo A, et al. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nat Commun. 2022;13:1373.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Posch F, Silina K, Leibl S, Mundlein A, Moch H, Siebenhuner A, et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology. 2018;7: e1378844.

Article  PubMed  Google Scholar 

Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 2015;112:1782–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35:571–80.

Article  CAS  PubMed  Google Scholar 

Rakaee M, Kilvaer TK, Jamaly S, Berg T, Paulsen EE, Berglund M, et al. Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. Br J Cancer. 2021;124:1680–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahn B, Ahn HS, Shin J, Jun E, Koh EY, Ryu YM, et al. Characterization of lymphocyte-rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures. Liver Int. 2024;44:1202–18.

Article  CAS  PubMed  Google Scholar 

Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol. 2019;70:58–65.

Article  PubMed  Google Scholar 

Liang H, Zhang Z, Guan Z, Zheng S, Lou J, Liu W, et al. Follicle-like tertiary lymphoid structures: a potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma. Front Immunol. 2023;14:1096220.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang WH, Wang WQ, Han X, Gao HL, Xu SS, Li S, et al. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. J Immunother Cancer. 2020;8:e001188.

Article  PubMed  PubMed Central  Google Scholar 

Frizziero M, Kilgour E, Simpson KL, Rothwell DG, Moore DA, Frese KK, et al. Expanding therapeutic opportunities for extrapulmonary neuroendocrine carcinoma. Clin Cancer Res. 2022;28:1999–2019.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dudnik E, Kareff S, Moskovitz M, Kim C, Liu SV, Lobachov A, et al. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. J Immunother Cancer. 2021;9:e001999.

Article  PubMed  PubMed Central  Google Scholar 

Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017.

Google Scholar 

Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 8th ed. Cham: Springer International Publishing, American Joint Commission on Cancer; 2017.

Google Scholar 

Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16:1235–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wickham H. ggplot2: elegant graphics for data analysis. 2nd ed. New York: Springer; 2016.

Book